Abstract
Recent advances in surgical techniques, bladder cancer molecular biology discoveries, access to point-of-care genomic biomarker platforms, and therapy options in metastatic bladder cancer patients suggest that significant improvements in the options and outcomes for patients with muscle-invasive bladder cancer (MIBC) are achievable. Indeed, multiple MIBC clinical trials with practice-changing impact are ongoing. This chapter provides a synopsis of the key populations, designs, and endpoints under investigation in these important MIBC trials.
Original language | English (US) |
---|---|
Title of host publication | Bladder Cancer |
Subtitle of host publication | A Practical Guide |
Publisher | Springer International Publishing |
Pages | 355-363 |
Number of pages | 9 |
ISBN (Electronic) | 9781484271070 |
ISBN (Print) | 9781484271063 |
DOIs | |
State | Published - Jan 1 2021 |
Keywords
- Bladder cancer
- Clinical trials
- Muscle-invasive
- Phase 2
- Phase 3
- Urothelial cancer
ASJC Scopus subject areas
- General Medicine